1. Home
  2. RGS vs BLRX Comparison

RGS vs BLRX Comparison

Compare RGS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regis Corporation

RGS

Regis Corporation

N/A

Current Price

$21.65

Market Cap

53.3M

ML Signal

N/A

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.68

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGS
BLRX
Founded
1922
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.3M
12.6M
IPO Year
1994
2010

Fundamental Metrics

Financial Performance
Metric
RGS
BLRX
Price
$21.65
$2.68
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
5.7K
9.4K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
20.24
N/A
EPS
0.64
N/A
Revenue
$210,134,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.81
N/A
Revenue Growth
3.52
N/A
52 Week Low
$15.00
$2.30
52 Week High
$31.50
$7.77

Technical Indicators

Market Signals
Indicator
RGS
BLRX
Relative Strength Index (RSI) 48.59 41.70
Support Level $21.19 $2.66
Resistance Level $23.67 $3.11
Average True Range (ATR) 0.98 0.18
MACD 0.02 -0.01
Stochastic Oscillator 72.66 23.92

Price Performance

Historical Comparison
RGS
BLRX

About RGS Regis Corporation

Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: